Trial: 202103086

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (auto-HCT) for Multiple Myeloma (MM)

Phase

II

Principal Investigator

Stockerl-Goldstein, Keith

Disease Site

Multiple Myeloma

Learn more about this study at: clinicaltrials.gov